Form 8-K - Current report:
SEC Accession No. 0001659617-20-000043
Filing Date
2020-03-04
Accepted
2020-03-04 07:31:59
Documents
13
Period of Report
2020-03-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-kq1shareholderletter.htm 8-K 20407
2 EXHIBIT 99.1 exh991-pressreleaseshareho.htm EX-99.1 8928
3 EXHIBIT 99.2 mbrx2020kickoffletterfin.htm EX-99.2 17851
4 mbrx2020kickoffletterfin001.jpg GRAPHIC 129660
5 mbrx2020kickoffletterfin002.jpg GRAPHIC 152985
6 mbrx2020kickoffletterfin003.jpg GRAPHIC 158488
7 mbrx2020kickoffletterfin004.jpg GRAPHIC 128600
8 mbrx2020kickoffletterfin005.jpg GRAPHIC 163134
9 mbrx2020kickoffletterfin006.jpg GRAPHIC 195538
10 mbrx2020kickoffletterfin007.jpg GRAPHIC 211402
11 mbrx2020kickoffletterfin008.jpg GRAPHIC 78602
12 moleculin-logo_horiza23.jpg GRAPHIC 132868
13 moleculinlogoa32.jpg GRAPHIC 11658
  Complete submission text file 0001659617-20-000043.txt   1915741
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

IRS No.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 20685685
SIC: 2834 Pharmaceutical Preparations